Resonance HealthASX:RHT +4.55% Current Ratio is 1.87 as of Dec. 2025, which is 69% below its 10-year median of 5.98. The stock has 6 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Resonance Health ranks better than 62.96% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Resonance Health's current ratio for the quarter that ended in Dec. 2025 was 1.87.
Resonance Health has a current ratio of 1.87. It generally indicates good short-term financial strength.
The historical rank and industry rank for Resonance Health's Current Ratio or its related term are showing as below:
ASX:RHT'
s Current Ratio Range Over the Past 10 Years
Min: 1.28 Med: 5.98 Max: 16.53
Current: 1.87
During the past 13 years, Resonance Health's highest Current Ratio was 16.53. The lowest was 1.28. And the median was 5.98.
ASX:RHT's Current Ratio is ranked better than 62.96% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs ASX:RHT: 1.87
Resonance Health (ASX:RHT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Resonance Health Current Ratio Related Terms
Resonance Health Current Ratio Historical Data
* Premium members only.
The historical data trend for Resonance Health's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Current Ratio Comparison
For the Health Information Services subindustry, Resonance Health's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Current Ratio distribution charts can be found below:
* The bar in red indicates where Resonance Health's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Current Ratio of 1.87 as of Dec. 2025. This is 69% below median its historical median of 5.98. Over the past decade, Resonance Health's Current Ratio has ranged from 1.28 to 16.53. According to the industry distribution chart, Resonance Health ranks #253 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 37%.
Is Resonance Health's Current Ratio too high?
Resonance Health's current Current Ratio of 1.87 is 69% below median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 16.53. The Healthcare Providers & Services industry median Current Ratio is 1.47. Resonance Health's value of 1.87 is 27.2% above this industry median. Based on the distribution chart, Resonance Health ranks #253 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's Current Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #253 out of 683 companies for Current Ratio. This puts Resonance Health in the upper half of its industry. The industry median Current Ratio is 1.47. Resonance Health's value of 1.87 is 27.2% above this benchmark. Historically, Resonance Health's own Current Ratio has ranged from 1.28 to 16.53 over the past decade. While the company's 10-year median is 5.98 vs. the industry median of 1.47, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Current Ratio of 1.87 is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Current Ratio is 1.87, which is 69% below median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current Current Ratio is 1.87, which is 69% below median its 10-year median of 5.98 and 27.2% above the Healthcare Providers & Services industry median of 1.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Current Ratio is 1.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 